EUCTR2008-001492-30-FR进行中（未招募）1 期
Comparison of the safety and efficacy of volinanserin and lormetazepam in the treatment of insomnia characterized by sleep maintenance difficulties. A 4 week, randomized, double-blind, double-dummy, comparative, parallel-group study. - REST
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 266
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written, signed and dated informed consent obtained (for patients accepting pharmacogenetic testing, specific written, signed and dated informed consent obtained);
- •2. Primary Insomnia according to DSM-IV-TR criteria (Appendix A), with predominantly difficulty in maintaining sleep for at least one month preceding the study visit, and having clinically significant distress or impairment in social, occupational or other important areas of functioning.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion criteria related to study methodology
- •1. Patients younger than 18 years;
- •2. Inpatients;
- •3. Based on patient’s information, the patient has spent less than 6.5 hours or more than 9.0 hours, in bed, each night, over the preceding two weeks;
- •4. Based on patient’s information, the patient complains of less than one hour of wakefulness after sleep onset for at least 3 nights per week over the preceding month;
- •5. Based on patient’s sleep questionnaire administered each morning during the run-in period, mean pr-WASO < 45 min (calculated on at least 4 nigths);
- •6. Based on patient’s sleep questionnaire administered each morning during the run-in period, mean pr-TST > 7 hours or < 3 hours (calculated on at least 4 nigths);
- •7. Based on patient’s sleep questionnaire administered each morning during the run-in period, mean pr-SOL > 30 min (calculated on at least 4 nigths);
- •8. Women of childbearing potential (less than 2 years of postmenopausal or not surgically sterile) without a negative urine ß-hCG test prior to entry into the study and who do not employ an acceptable method of birth control for this study for one month prior to entry into the run-in, throughout the study, and one month after study medication administration is stopped. Acceptable methods are the following: IUDs, depot, implant and trans-dermal estrogens-progesterones alone, combined oral contraceptives, sterilization, and double barrier methods in conjonction with permicide, vasectomized partner, and sexual abstinence. (Unless not acceptable by local health authorities);
- •9. Females who are pregnant or breastfeeding;
- •10. Night shift workers and individuals who nap 3 or more times per week over the preceding month (a nap being defined by an intentional sleep of more than 20 minutes);
- •11. Consumption of xanthine-containing beverages (i.e., tea, coffee or cola) that comprises more than 5 cups or glasses per day;
- •12. Patient unable to participate for the entire duration of the study or unable to complete study questionnaires or, in the opinion of the investigator has the potential to be non compliant with the obligations inherent in trial participation;
- •13. Participation in another clinical trial within 1 month before the screening visit;
- •14. Participation (randomization) in a previous volinanserin trial;
- •15. Based on medical history and patient’s information: primary hypersomnia, narcolepsy, breathing related sleep disorders, circadian rhythm sleep disorder, parasomnia (e.g., somnambulism), dyssomnia not otherwise specified (i.e., periodic leg movement);
- •16. Current severe neuropsychiatric disorders (i.e., psychosis, obsessive compulsive disorder, major depression, anxiety disorders, panic disorders, dementia of Alzheimer’s or vascular type) according to DSM-IV-TR criteria or mental retardation;
- •17. Insomnia secondary to a general medical condition;
- •18. Substance dependence or substance abuse within the last year (except nicotine, DSM-IV-TR criteria);
- •19. Acute or unstable chronic disease that in the opinion of the Investigator, would compromise the patient’s safety or successful participation in the study or that might interfere with the evaluation of study medication;
- •20. Evidence of any significant laboratory or ECG finding at screening which the investigator judges incompatible with the investigation of a new chemical entity;
- •21. Use of any over-the-counter (OTC) medications (including tryptophan, valerian, kavakava, melatonin and St John’s Wort) or prescription sleep
研究者
相似试验
进行中（未招募）
不适用
Comparison of the safety and efficacy of volinanserin and lormetazepam in the treatment of insomnia characterized by sleep maintenance difficulties. A 4 week, randomized, double-blind, double-dummy, comparative, parallel-group study. - RESTInsomnia characterized by sleep maintenance difficultiesMedDRA version: 11.0Level: LLTClassification code 10027590Term: <Manually entered code. Term in E.1.1>EUCTR2008-001492-30-SEsanofi-aventis recherche & développement266
进行中（未招募）
不适用
Comparison of the safety and efficacy of volinanserin and lormetazepam in the treatment of insomnia characterized by sleep maintenance difficulties. A 4 week, randomized, double-blind, double-dummy, comparative, parallel-group study. - RESTInsomnia characterized by sleep maintenance difficultiesMedDRA version: 11.0Level: LLTClassification code 10027590Term: <Manually entered code. Term in E.1.1>EUCTR2008-001492-30-NLsanofi-aventis recherche & développement266
尚未招募
4 期
Comparison of various antihypertensive medicines in patients of high blood pressureCTRI/2018/05/014011Jawaharlal Nehru Medical College
已完成
4 期
A study to compare drugs Vortioxetine and Escitalopram, used for treatment of DepressioCTRI/2019/11/022030Dr Anshul Upadhyay60
进行中（未招募）
1 期
Comparison of effectiveness and safety of vaginally used Dequalinium Chloride with orally taken Metronidazole in the treatment of bacterial vaginosisBacterial vaginosisEUCTR2020-002489-15-SKMedinova AG236